BioSpace News Archive

Veru Inc. announced that it received a delinquency notification letter from the Listing Qualifications staff of the Nasdaq Stock Market LLC on February 21, 2024 due to the Company’s non-compliance with Nasdaq Listing Rule 5250 as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023.

Oragenics, Inc. announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock at a public offering price of $1.50 per share, for gross proceeds of $2.1 million, before deducting underwriting discounts and offering expenses payable by the Company.